Open AccessPrediction of infection risk in rheumatoid arthritis patients treated with biologics: are we any closer to risk stratification?
Author(s) -
Meghna Jani,
Anne Barton,
Kimme L Hyrich
Publication year - 2019
Publication title -
current opinion in rheumatology/current opinion in rheumatology, with evaluated medline
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.452
H-Index - 112
eISSN - 1080-8175
pISSN - 1040-8711
DOI - 10.1097/bor.0000000000000598
Subject(s) - medicine , rheumatoid arthritis , etanercept , observational study , intensive care medicine , tocilizumab , population , risk assessment , environmental health , computer security , computer science
There are currently several available biologics for rheumatoid arthritis (RA) with similar efficacy in most trials. A major consideration therefore in choosing a biologic, continues to be safety concerns such as infection. Considerable advances have been made in the understanding of biologic safety on a population level; however, how close are we to stratifying risk for individual patients? This review discusses evidence published in the last year, with reference to key previous literature.